Closely held Amphista Therapeutics has announced the appointments of Dr. Lisa Butler as SVP of clinical operations, Dr. Alexandra Sevko as VP of translational science, and Nicola Lindsay as head of project and portfolio management.
According to Amphista, these appointments will serve to strengthen its clinical development capabilities and accelerate its objective of bringing Targeted Glue protein degraders to patients with severe diseases. The company is focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disorders, through the discovery of advanced, next-gen targeted protein degradation (TPD) medicines.
Dr. Lisa Butler brings more than 25 years of clinical research leadership to Amphista, spanning small biotechs and global pharmaceutical companies, including AstraZeneca; Dr. Alexandra Sevko brings more than 20 years of experience in immuno-oncology and translational research across prestigious academic institutions and industry including Imperial College London, University College London and Adaptimmune; and with more than 25 years of industry experience, Nicola Lindsay joins Amphista from NodThera.
In a statement, Martin Pass, CDO at Amphista, commented, “As we prepare to enter the clinic next year with our lead asset, AMX-883, we are delighted to be able to announce the appointment of these three exceptional leaders. The high-calibre expertise that we have assembled will be instrumental to the successful execution of our clinical programmes, and in establishing a strong foundation to support future growth and deliver on our mission to bring transformative TPD medicines to patients.”
